Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Peyrin-Biroulet L, Hart A, Bossuyt P, Long M, Allez M, Juillerat P, Armuzzi A, Loftus E, Ostad-Saffari E, Scalori A, Oh Y, Tole S, Chai A, Pulley J, Lacey S, Sandborn W, HICKORY Study Group. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. Lancet Gastroenterol Hepatol 2021; 7:128-140.
Nov 17, 2021
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Nov 17, 2021
Lancet Gastroenterol Hepatol 2021; 7:128-140
Peyrin-Biroulet Laurent, Hart Ailsa, Bossuyt Peter, Long Millie, Allez Matthieu, Juillerat Pascal, Armuzzi Alessandro, Loftus Edward V, Ostad-Saffari Elham, Scalori Astrid, Oh Young S, Tole Swati, Chai Akiko, Pulley Jennifer, Lacey Stuart, Sandborn William J, HICKORY Study Group
more
